# Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

> **NCT00523380** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 10 (actual)

## Conditions studied

- Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** recombinant interleukin-21
- **DRUG:** caelyx (pegylated liposomal doxorubicin)

## Key facts

- **NCT ID:** NCT00523380
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-04
- **Primary completion:** 2009-01-07
- **Final completion:** 2009-01-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523380, "Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00523380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*